Home » Newsletters » BioWorld Science

BioWorld Science

April 23, 2003

View Archived Issues

Benzimidazole CDK4 inhibitors under study at Aventis

Merck scientists present a novel GABA-A agonist for use in anxiety and convulsions

Fuji Photo Film claims new contrast agents for the diagnosis of vascular disorders

New HIV protease inhibitors in early development at BMS

Pfizer patent covers novel thyroid receptor ligands and their use

Dithiazole-based MMP inhibitors newly discovered at Shiseido

Vitamin E analogue sensitizes Jurkat cells by suppressing NF-kB activation

Restructuring update at CeNeS

Arava approved for rheumatoid arthritis in Japan

Ketek may exacerbate symptoms of myasthenia gravis

Vilazodone results fail to support progression to phase III

Northwest Biotherapeutics receives NCI grant for tumor growth inhibition

Nastech reacquires intranasal apomorphine rights following Pfizer-Pharmacia merger

DynPort completes smallpox vaccine phase I trial

Patient treatment begins in phase I trial of VIT-100

Phase II studies of ILX-651 planned

Virulizin phase III trial extended to Canada and Mexico

Ribozyme changes name

AGI Dermatics regains rights to Dimericine

Novo Nordisk and Fournier sign repaglinide comarketing deal for Europe

Vasopeptidase inhibitor as effective as ACE inhibitor in old SHR

Tricyclic bis-enone compounds as inhibitors of NO production

Profile of SLV-310, a potential antipsychotic agent

5-HT6 receptor-selective antagonist reverses cognitive deficits in animal model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 13, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
LINC01116 has prognostic value in lung cancer, study shows
BioWorld MedTech
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...